MED22

Across TCGA pan-cancer cohorts, MED22 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MED22 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MED22 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MED22 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where MED22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.239	0.695	.006	13	view →
HNSC	DFS	Median	All	0.983	0.921	.008	8	view →
CCRCC	OS	Median	All	0.712	1.000	.019	7	view →
LSCC	DFS	Tertile	II,III,IV	0.852	0.506	.013	6	view →
OV	DFS	Median	All	0.843	1.000	.017	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MED22–PDAC (OS)

Open the PDAC breakdown →